0000891293-22-000034.txt : 20220706 0000891293-22-000034.hdr.sgml : 20220706 20220706171943 ACCESSION NUMBER: 0000891293-22-000034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Craig Adam R CENTRAL INDEX KEY: 0001339498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 221069737 MAIL ADDRESS: STREET 1: C/O INNOVIVE PHARMACEUTICALS, INC. STREET 2: 555 MADISON AVENUE, 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2022-06-30 0 0000891293 CTI BIOPHARMA CORP CTIC 0001339498 Craig Adam R 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 1 1 0 0 President and CEO common stock 2022-06-30 4 A 0 6183 2.1165 A 22861 D common stock 2022-07-01 4 M 0 27000 0.8411 A 49861 D common stock 2022-07-01 4 S 0 27000 6 D 22861 D common stock 2022-07-05 4 M 0 27000 0.8411 A 49861 D common stock 2022-07-05 4 S 0 27000 6 D 22861 D common stock 2022-07-06 4 M 0 18223 0.8411 A 41084 D common stock 2022-07-06 4 S 0 18223 6.11 D 22861 D Non-Qualified Stock Option (right to buy) 0.8411 2022-07-01 4 M 0 27000 0 D 2029-05-16 Common Stock 27000 1200777 D Non-Qualified Stock Option (right to buy) 0.8411 2022-07-05 4 M 0 27000 0 D 2029-05-16 Common Stock 27000 1173777 D Non-Qualified Stock Option (right to buy) 0.8411 2022-07-06 4 M 0 18223 0 D 2029-05-16 Common Stock 18223 1155554 D Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Adam R. Craig 2022-07-06